bioAffinity Technologies Reports Q3 2026 Results and 79% Year-to-Date Testing Revenue Growth
bioAffinity Technologies reported Q3 2026 revenue of $1.1M and a net loss of $5.3M. CyPath Lung test sales doubled year-to-date, with testing revenue up 79%. The company had $2.6M in cash at quarter-end. Operating loss widened to $3.5M from $2.3M a year earlier. Physician orders and test reports increased significantly, and the company expanded its distribution network and research collaborations.
How this was made
The 30-second read
Why it matters
Investors will likely focus on whether testing growth can offset operating losses and whether the reduced cash balance implies additional capital needs before clinical and commercialization milestones.
Market read
The combination of operational traction in CyPath Lung testing and a sharp cash decline with larger net loss creates a near-term risk-reward inflection for the stock.
What to watch
The article notes a subsequent financing and expanding government healthcare distribution, which may reduce dilution risk if it translates into sustained test report growth beyond the first nine months.
Background
bioAffinity Technologies is a diagnostics and therapeutics-focused biotech; this update centers on CyPath Lung testing performance, pipeline progress, and balance-sheet liquidity.
Ticker impact
bioAffinity Technologies reported Q3 2026 revenue of $1.07M, net loss of $5.28M, and cash of $2.55M at Sept. 30, 2026.
Likely downside pressure as investors weigh the cash burn and shrinking cash balance against testing growth and pipeline progress.
The article discloses hard financial datapoints (revenue down YoY, net loss up, cash down materially) plus operational traction (ordering physicians and test volumes up), which can be offset by dilution/financing concerns.
Market effects
Small-cap in vitro diagnostics and molecular testing names may see sentiment spillover from cash runway and commercialization-readiness signals.
Limited, primarily affects US small-cap biotech/diagnostics sentiment.
Low, as the disclosed items are company-specific and not a global macro catalyst.
Counterpoint
CyPath Lung testing momentum (ordering physicians up 89% YoY, test volumes up 48% for existing physicians) could outweigh near-term cash concerns if the subsequent $4.0M financing extends runway into commercialization milestones.
Key entities
- companybioAffinity Technologies, Inc.
Reported Q3 2026 financial results, CyPath Lung testing growth, and cash position, plus updates on distribution and R&D/IP.
- productCyPath Lung
Lung test platform whose unit sales and testing revenue increased during 2026 year-to-date.
- partnerAvMEDICAL
Named in an agreement expanding government healthcare distribution network.
- collaboration partnerPictor
Collaborator supporting next-generation sputum-based diagnostic development.
